Wedbush Estimates Pharvaris' Q3 Earnings (NASDAQ:PHVS)

Key Points

• Wedbush analysts have revised their Q3 2025 EPS forecast for Pharvaris, improving it from ($0.87) to ($0.77), and maintain an "Outperform" rating with a price objective of $27.00.
• Pharvaris reported a Q3 earnings miss with an EPS of ($0.94), falling short of the consensus estimate of ($0.87) by $0.07.
• Several other analysts have adjusted their price targets for Pharvaris, with Cantor Fitzgerald lowering theirs from $28.00 to $25.00, indicating a trend of cautious sentiment around the stock.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Research analysts at Wedbush upped their Q3 2025 earnings estimates for Pharvaris in a report released on Wednesday, August 13th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.77) per share for the quarter, up from their prior estimate of ($0.87). Wedbush has a "Outperform" rating and a $27.00 price target on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Pharvaris' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.49) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.82) EPS, FY2027 earnings at ($1.65) EPS and FY2028 earnings at $0.73 EPS.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.07).

Several other analysts have also commented on PHVS. Guggenheim assumed coverage on Pharvaris in a report on Wednesday, June 11th. They issued a "buy" rating and a $32.00 price objective on the stock. JMP Securities decreased their target price on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating on the stock in a research report on Wednesday, August 13th. Cantor Fitzgerald dropped their price target on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Finally, Zacks Research upgraded shares of Pharvaris from a "strong sell" rating to a "hold" rating in a research report on Monday. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $35.60.

Pharvaris Price Performance

NASDAQ PHVS traded down $0.22 during trading hours on Friday, reaching $23.04. The company's stock had a trading volume of 18,743 shares, compared to its average volume of 79,733. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -6.86 and a beta of -2.81. The company's 50-day moving average is $19.90 and its two-hundred day moving average is $17.31. Pharvaris has a 1-year low of $11.51 and a 1-year high of $26.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PHVS. Soleus Capital Management L.P. increased its holdings in shares of Pharvaris by 36.2% in the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after purchasing an additional 216,483 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock valued at $14,914,000 after buying an additional 157,530 shares in the last quarter. Rock Springs Capital Management LP increased its stake in shares of Pharvaris by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock worth $14,859,000 after acquiring an additional 18,200 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after acquiring an additional 118,408 shares during the period. Finally, TFG Asset Management GP Ltd boosted its position in shares of Pharvaris by 48.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company's stock valued at $3,311,000 after acquiring an additional 61,105 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.